
Leandro Jonata Carvalho Oliveira: Added Clinical Impact of the Oncotype DX Assay
Leandro Jonata Carvalho Oliveira, MD Medical Oncologist at Grupo Oncoclinicas. shared on LinkedIn about a recent paper published on ScienceDirect:
“Just out in The Breast: a multicenter, real-world study from GBECAM evaluating the added clinical impact of the Oncotype DX assay in HR+/HER2- early breast cancer.
In this retrospective analysis, a small and highly selected subgroup of patients – eligible for adjuvant CDK4/6i but with low/intermediate genomic risk by ODX-achieved excellent 5-year outcomes with ET alone:
- 95-100% postmenopausal
- 80% with only 1N+
- Among monarchE-eligible: 70% met Cohort 2 only.
These findings underscore the importance of integrating biologic/genomic features into clinical/anatomic evaluation to refine risk stratification and guide personalized treatment decisions.
We still face an urgent need to expand access to genomic signatures for Brazilian patients with HR+/HER2- eBC.
My sincere thanks to GBECAM – Brazilian Group for Breast Cancer Studies, all co-authors and participating centers, and especially our senior author, Dr. Max Mano, for their invaluable contributions.”
Title: Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study
Authors: Leandro Jonata de Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, Daniele Assad-Suzuki, Daniel Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Aliosha Kaliks, Debora de Melo Gagliato, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Carlos Henrique dos Anjos, Rudinei Linck, Thais Baccili Cury Megid, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Max Senna Mano
More posts featuring Leandro Jonata Carvalho Oliveira.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023